ReviewEndocrinology and metabolism (Seoul, Korea)2020
Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification.
Review in Endocrinology and metabolism (Seoul, Korea), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Article
- Article
- Recurrence Rate and Survival in 260 Patients With Oncocytic Thyroid Cancer According to Response to Initial Treatment - A Single-Institution Experience.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Establishment of a nomogram model for predicting distant metastasis in oncocytic thyroid carcinoma: A retrospective cohort study.Medicine · 2026Article
- Acetate Metabolism in Thyroid Cancer Progression.International journal of molecular sciences · 2026Article
- Article
- Genomic profiling of a DICER1-wildtype thyroblastoma reveals AGK-BRAF fusion, EIF1AX duplication, and TERT promoter mutations: integrated genomic and pathway analysis.Frontiers in endocrinology · 2026Article
- Pentraxin-3 in thyroid nodules: a systemic marker of pathology and a local mediator of inflammation and carcinoma.Frontiers in endocrinology · 2026Article
- Diagnostic Significance of Trophoblast Cell Surface Antigen-2 Expression in Benign and Malignant Thyroid Lesions.Cureus · 2025Article
- Clinical outcome and influencing factors of differentiated thyroid cancer with biochemical incomplete response.Future oncology (London, England) · 2025Article
- Diagnostic impact of DNA methylation classification in adult and pediatric CNS tumors.Scientific reports · 2025Article
- Clinico-pathological factors and [BMC medical imaging · 2024Article
- Molecular Markers in Follicular and Oncocytic Thyroid Carcinomas: Clinical Application of Molecular Genetic Testing.Current oncology (Toronto, Ont.) · 2024Article
- Clinical, Pathological, and Immunohistochemical Predictors of Cause-Specific Mortality in Papillary Thyroid Cancer: Multivariate Analysis.Bulletin of experimental biology and medicine · 2024Article
- Clinical-Pathological Features of Thyroid Neoplasms in Young Patients Diagnosed in a Single Center.Life (Basel, Switzerland) · 2024Article
- A patient with a rare co-occurrence of papillary and follicular thyroid carcinomas.Clinical case reports · 2024Article
- "Examining the link between tooth agenesis and papillary thyroid cancer: is there a risk factor?" Observational study.Progress in orthodontics · 2024Observational
- Coexistence of intrathyroid thymic carcinoma and papillary thyroid carcinoma: a case report and literature review.Frontiers in oncology · 2024Article
- Retrospective study of BRAFPeerJ · 2024Article
- Agrin is a novel oncogenic protein in thyroid cancer.Oncology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Advances in medical sciences and evidence-based medicine have led to momentous changes in classification and management of thyroid neoplasms. Much progress has been made toward avoiding overdiagnosis and overtreatment of thyroid cancers. The new 2017 World Health Organization (WHO) classification of thyroid neoplasms updated the diagnostic criteria and molecular and genetic characteristics reflecting the biology and behavior of the tumors, and newly introduced the category of borderline malignancy or uncertain malignant potential. Some neoplasms were subclassified, renamed, or redefined as a specific entity. This review introduces changes in the fourth edition WHO classification of thyroid tumors and updates the contemporary diagnosis and classification of thyroid tumors. We also discuss several challenges with the proposal of new diagnostic entities, since they have unique histopathologic and molecular features and clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.